
Kies je etiket
direct zichtbaar op de vial7 labrapporten
PDF- Getest
- Retatrutide 10mg
- Lab
- Analiza Białek
- Datum
- November 2026
- Resultaat
- 99% purity (10.37 mg measured)
- Endotoxinen
- 5.54 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 15mg
- Lab
- Analiza Białek
- Datum
- November 2026
- Resultaat
- 99% purity (16.53 mg measured)
- Endotoxinen
- 5.91 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 30mg
- Lab
- Analiza Białek
- Datum
- November 2026
- Resultaat
- 99% purity (31.88 mg measured)
- Endotoxinen
- 6.29 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 40mg
- Lab
- Analiza Białek
- Datum
- November 2026
- Resultaat
- 99% purity (40.92 mg measured)
- Endotoxinen
- 6.82 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 60mg
- Lab
- Analiza Białek
- Datum
- November 2026
- Resultaat
- 99% purity (60.10 mg measured)
- Endotoxinen
- 7.73 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 20mg
- Lab
- Analiza Białek
- Datum
- October 2026
- Resultaat
- 99% purity (23.28 mg measured)
- Endotoxinen
- 6.15 EU/vial
- Bestelnr.
- Wachtwoord
PDF- Getest
- Retatrutide 5mg
- Lab
- Analiza Białek
- Datum
- July 2026
- Resultaat
- 99% purity (5.28 mg measured)
- Bestelnr.
- Wachtwoord
Onafhankelijk getest, met het wachtwoord direct bij het lab te controleren.
Retatrutide
GLP-1
- Laboratoriumgetest · 99% zuiverheid
- Verzonden vanuit Duitsland
Bestelling
- DHL met tracking
- Discrete verpakking
4.6 van 5 op Trustpilot73 reviews
Ook gezocht als: Retatrutid · Reta · LY3437943
In één oogopslag
Retatrutide in cijfers
De kerncijfers uit ons lexicon. Sleep het punt langs de curve om te zien hoeveel er na één dosis rekenkundig nog over is.
Volledig lexiconartikelHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~6 days
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
~6days
- Class
- Triple agonistGLP-1 / GIP / glucagon
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 5 to 60 mg11 sizes in the shop
What studies show
All 10 sources in the lexicon- up to25 %
Phase 3 trial TRIUMPH-1 in obesity (up to 25% weight reduction at 80 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2026 - up to18.8 %Bellido et al., The Lancet, 2026
- up to~24 %
Phase 2 study in obesity (up to ~24% weight reduction at 48 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2023
Kennis
Alles over Retatrutide
Uitgebreide informatie volgt binnenkort.
Dosering
Doseringsinformatie laden …
Handig om erbij te hebben
Wat je erbij nodig hebt
Bacteriostatisch water wordt automatisch aan je winkelwagen toegevoegd. Spuiten en doekjes met één klik.
Insulinespuiten
10 stuks · 5.50 €
Alcoholdoekjes
50 stuks · 10 €
Hoeveel water?
Eenheden op de spuit voor jouw vialgrootte.
Naar de calculator →Is Retatrutide approved?
No, as of 25 October 2026 there is no approval. Retatrutide is in phase 3: 14 phase 3 trials are listed on ClinicalTrials.gov, five of them completed. The first phase 3 results were published in 2026.
How does Retatrutide differ from Tirzepatide and Semaglutide?
The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GLP-1 and GIP. Retatrutide also targets the glucagon receptor. In animal models this added higher energy expenditure. A head-to-head trial against Tirzepatide is still running (TRIUMPH-5).
What did the phase 3 trials show?
In TRIUMPH-1 (obesity without diabetes) weight fell by 25.0 percent on average after 80 weeks at the highest study dose, by 3.9 percent on placebo. In TRIUMPH-2 (with type 2 diabetes) it was 18.8 versus 5.1 percent. In TRANSCEND-T2D-1 long-term blood sugar (HbA1c) fell by up to 1.94 percentage points in 40 weeks.
What happens to liver fat?
In a substudy with fatty liver (MASLD) liver fat fell by about 81 to 82 percent after 24 weeks in the two higher levels. 86 percent reached normal liver fat below 5 percent at the highest level. A large phase 3 trial on liver disease runs until 2030.
Which side effects were seen?
Most often gastrointestinal effects such as nausea and diarrhoea, depending on the dose. In TRIUMPH-2 abnormal skin sensations (dysaesthesia) and low blood pressure occurred more often than on placebo. In the phase 2 trial heart rate rose in a dose-dependent way, most around week 24.
Which trials are still running?
Nine phase 3 trials are not finished yet. The largest: TRIUMPH-OUTCOMES on heart and kidney events with about 10,000 participants (planned end 2029) and SYNERGY-Outcomes on fatty liver (2030). The comparison with Tirzepatide (TRIUMPH-5) is due to reach its primary endpoint in November 2026.
Vergelijkingen
Hoe het zich verhoudt
Gerelateerd
Gerelateerde producten
Tirzepatide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
10 maten
Laboratoriumgetest
= vanaf 10 €/vial
Semaglutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
6 maten
Laboratoriumgetest
= vanaf 10 €/vial
Mazdutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
2 maten
= vanaf 32 €/vial
Survodutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
1 maat
= 60.8 €/vial
Retatrutide

